Podcasts about Harpreet Singh

We're in Munich

For this episode, I spoke with Harpreet Singh (@singh_harpreet), Co-CEO and Co-Founder of Launchable Inc., on building a next gen DevOps practice, with strategies for accelerating your product and software delivery/ You can find more information on my guest on my blog at https://buckleyplanet.com/2024/06/collabtalk-podcast-episode-130-with-harpreet-singh/

Today, we have a special guest, Harpreet Singh, the co-founder and co-CEO of Launchable. Harpreet joins us to discuss an exciting frontier in software testing—using machine learning to predict failures and streamline the testing process. Imagine a tool that can intelligently shift tests left in the development cycle, prioritize the most critical tests based on risk, and notify you via Slack when issues arise—all while continually learning and improving. This is precisely what Harpreet and his team have achieved with Launchable. Their platform integrates seamlessly into CI/CD pipelines and provides engineering teams with valuable insights to speed up the process of identifying and fixing test failures. In this episode, we'll delve into how Launchable aids in catching issues earlier, the profound influence of AI on the testing landscape, and real-life examples like BMW that illustrate the solution's effectiveness. We'll also explore Harpreet's advice on adopting a targeted approach to AI in DevOps and how their solution alleviates cognitive load, saving developers time and effort. Try out SmartBear's Bugsnag for free, today. No credit card required. https://links.testguild.com/bugsnag  

This podcast interview focuses on the entrepreneurial journey to solve the non-trivial testing problems of some companies that we all blindly rely on . My guest is Harpreet Singh, Co-CEO of Launchable. Harpreet is an entrepreneur, innovator, developer, creative product leader, and seasoned DevOps leader who has dedicated his life to building new solutions for software teams. He's got extensive product marketing & Product management experience at Sun Microsystems.  Then helped CloudBees find product market fit and create a business based on OSS that scaled to multi-millions in ARR. Then moved to Atlassian where be became the GM for Atlassian Bitbucket, where he helped set the blueprint of what became the strategy at Atlassian to embrace DevOps tools in the market. In September 2019 he co-founded Launchable and shares the CEO role.   Their mission: Help dev teams launch fearlessly. Their point of view: 80% of software tests are pointless. We'll help you see the 20% that matters most. And this inspired me, and hence I invited Harpreet to my podcast. We explore what's broken around software testing these days. Harpreet provides his vision of how to address this. He elaborates on the journey of building an AI-powered software delivery platform and shares his most valuable go-to-market lessons - particularly why he didn't opt for a product-led growth motion and how he avoided getting stuck in red oceans. Last but not least, he shares his advice to peer SaaS CEOs on scaling their businesses while staying true to their core mission. Here's one of his quotes I spent a year and a half at Atlassian. They are the Gurus of product lead growth. So I got to see that close enough. And I came in and said we should probably do this. And I came to the realization that it's not one size fits all. Different teams have different needs, and the kinds we are serving have very different needs, then this product led growth. During this interview, you will learn four things: His lessons on how to simplify customer communication so it resonates optimally.  His advise on how to go beyond the obvious and find the biggest possible problem to solve for your ideal customers. How to choose your Go-to-Market model and what specifics to look for  How he landed BMW as one of his early customers and what that taught him. For more information about the guest from this week: Harpreet Singh Website: Launchable Subscribe to the Daily SaaS Reflection Get my free, 1 min daily reflection on shaping a B2B SaaS business no one can ignore. Subscribe here Yes, it's actually daily. And yes, people actually stay subscribed (Just see what peer B2B SaaS CEOs say) My promise: It's short. To the point. Inspiring. And valuable. Learn more about your ad choices. Visit megaphone.fm/adchoices

1330 In today's high-speed tech landscape, the difference between leading and lagging behind can be determined by how efficiently we test our software. Our next guest is at the forefront of transforming this crucial phase of development, ensuring that teams are not just running faster, but smarter. By leveraging machine learning to pinpoint the 20% of tests that provide 80% of the value, he has redefined what it means to be proactive in the software development world. Companies now spend less while achieving more, thanks to shorter testing loops and happier development teams. Get ready to dive deep into the future of software testing and development with the visionary behind Launchable, Harpreet Singh! Website: launchableinc.com Social Media: linkedin.com/singhharpreet ________ Go to www.BusinessBros.biz to be a guest on the show or to find out more on how we can help you get more customers! #Businesspodcasts #smallbusinesspodcast #businessmarketingtips #businessgrowthtips #strategicthinking #businessmastery #successinbusiness #businesshacks #marketingstrategist #wealthcreators #businessstrategies #businesseducation #businesstools #businesspodcast #businessmodel #growthmarketing #businesshelp #businesssupport #salesfunnel #buildyourbusiness #podcastinglife #successgoals #wealthcreation #marketingcoach #smallbusinesstips #businessmarketing #marketingconsultant #entrepreneurtips #businessstrategy #growyourbusiness Want to create live streams like this? Check out StreamYard: https://streamyard.com/pal/d/6164371927990272 --- Support this podcast: https://podcasters.spotify.com/pod/show/businessbrospod/support

Shiv our host is in conversation with Harpreet SIngh, CO-founder and co-CEO of Launchale Inc. Harpreet has been associated with conceiving and launching many innovative products that have become a standard among developer community. In today's conversation he talks aboutHow he started his career in India and then moved to the US. He emphasizes the importance of continuous learning and self-improvement. He mentions his growth mindset and his habit of reading and taking courses to stay updated.Harpreet acknowledges the challenge of scaling himself as a leader alongside the company. He talks about managing time for both work and personal growth. He highlights the importance of clear communication and context setting to empower his team and free up his time. He also mentions using a prioritization technique where he identifies the top three important tasks for both work and personal life. Harpreet acknowledges the resistance developers often have towards documentation. He discusses how he built his team by looking for individuals who value clear communication and writing skills. He describes how he identified a niche in the developer experience (DevEx) domain. He noticed that even after implementing CI/CD practices, companies weren't seeing the desired benefits quickly enough. This led him to explore how AI and machine learning could improve software delivery pipelines.Launchable's product uses machine learning to predict which tests are likely to fail based on code changes. Launchable is now expanding its offering to include intelligent test failure diagnostics using AI and machine learning.Harpreet acknowledges that coding style can influence the likelihood of errors. Launchable considers this to some extent, but the focus is on broader patterns and historical data to predict test failures.He emphasizes the importance of lifelong learning for personal and professional growth.He also talks about careers in testing and tech in general: Harpreet is an entrepreneur, innovator, developer, and creative product leader who has dedicated his life to building new solutions for software teams. His latest iteration is Launchable Inc, an AI/ML company to help developers and QA. A seasoned DevOps leader, Harpreet has been building products for developers for the last 25+ years.Previously, he was GM for Atlassian Bitbucket and VP of Product at CloudBees. At CloudBees he helped create the Jenkins business that scaled to multi-millions in ARR.He has an MBA from Santa Clara University, an MS in CS from the University of Cincinnati, and a Bachelors in Computer Engineering from Pune University, India.

This week, Teja talks with Harpreet Singh, Co-CEO and Co-Founder of Launchable, a company that's on a mission to make software testing faster and smarter. They discuss the DACI framework and the importance of intentionality in decision-making, what it's like to bring a behemoth like Jenkins to life, and the power of slowing down to meditate.https://www.launchableinc.com/ Hosted on Acast. See acast.com/privacy for more information.

The episode delves into the challenges faced by corporates in competitive acquisition processes and discusses strategies for corporate success in M&A. The main themes include the decline in success rates of corporates compared to financial investors, understanding the reasons behind this trend, and highlighting areas where corporates can adapt their approach to enhance their acquisition strategies.Key points/topics covered:Volatility in M&A marketsChallenges faced by corporates in competitive processesStrategies for corporate success in M&AImportance of governance and process in M&AMitigating internal capability challengesJoin us for an in-depth conversation on strategic approaches to improve the customer acquisition journey and gain a competitive advantage in the M&A landscape.Connect with our experts on LinkedIn:Phil Roux, Partner, L.E.K. Consulting: https://www.linkedin.com/in/pgdroux/Harpreet Singh, Partner, L.E.K. Consulting: https://www.linkedin.com/in/harpreet-singh-95354514/Tom Marshall, Principal, L.E.K. Consulting: https://www.linkedin.com/in/tom-marshall-1078671b/ Visit L.E.K. Consulting at https://www.lek.com/

211.ਹਰਪ੍ਰੀਤ ਸਿੰਘ ਦਾ ਤਿੰਨ ਵਾਰ ਸੱਚਖੰਡ ਜਾਣਾ।Harpreet Singh went to sachkahnd.

Third-party password managers can seem like a daunting, and unnecessary accessory to anyone's internet experience. They can be costly, and most people assume if they can remember their password, who cares? Turns out, if you can easily remember your password, an attacker could probably guess it eventually anyway. To continue our Cybersecurity Awareness Month series, Harpreet Singh from Talos Incident Response joins Jon to talk about password managers. They discuss the upside of using a third-party service like 1Password or LastPass, the potential dangers of using built-in browser password managers like Google Chrome and Safari, and other good password hygiene advice. 

Welcome to another episode of Category Visionaries — the show that explores GTM stories from the tech's most innovative B2B founders. In today's episode, we're speaking with Harpreet Singh, Co-Founder and Co-CEO of Launchable, a software testing platform that has raised over $12 Million in funding. Launchable is at the forefront of revolutionizing software testing by significantly reducing testing times through predictive test selection, leveraging machine learning to enhance development efficiency.   Here are the most interesting points from our conversation: Harpreet's Transition from Big Companies to Startups: After spending a decade at Sun Microsystems, Harpreet discovered his preference for the dynamic startup environment, leading to roles at CloudBees and Atlassian before launching his venture, highlighting the journey from an engineer to an entrepreneur. Admiration for People-focused Leadership: Harpreet respects founders who prioritize building a great culture and listening to their team. He aims to replicate these values at Launchable, demonstrating the impact of leadership style on company culture and growth. The Co-CEO Model's Success: Drawing inspiration from Atlassian, Harpreet and his co-founder adopted the Co-CEO model, finding it beneficial for making balanced decisions and dividing responsibilities based on strengths, which has contributed significantly to Launchable's strategic development. Innovative Solution to a Common Problem: Launchable addresses the inefficiency in software testing by introducing predictive test selection. This solution, which reduces testing times by up to 80%, showcases the company's commitment to enhancing the software development lifecycle. Strategic Early Customer Engagement: Securing BMW as an early customer through a product advisor program was pivotal. It not only validated Launchable's market fit but also demonstrated the potential for startups to engage with large enterprises effectively. Vision for the Future and Category Creation: Harpreet shares his vision for Launchable's future, focusing on expanding the scope of their solution to encompass broader issues in the bug and issue triaging space. This ambition illustrates the company's goal to define a new subcategory within software testing, emphasizing test failure intelligence and management.

On this Father's day episode, Nadir Pop and Peter Pop are joined by Harpreet Singh Grover, the Curious Parent. They discuss Hapreet shift into parenting research from an  entrepreneur, his thoughts on the changes in parenting in India and even the concept of Father's Day.  Harpreet is an independent researcher in the field of parenting and children. He posts as The Curious Parent on Instagram. (https://www.instagram.com/thecuriousparent.harpreet/) Before that he spent 12 years in EdTech building CoCubes which was acquired by Aon Hewitt in 2017. He is also the author of the no-bull shit book on entrepreneurship called Let's Build a Company published by Penguin. And an angel investor/coach with 50 odd start-ups including Ola, Ola Electric, Chaayos, Bombay Shaving Company and 15+ EdTech start-ups.  Beyond work, he has been mountaineering for 12 years and completed a few 100km+ trail running races in 2019. After this Harpreet tried to convince his wife to live in the hills. Failing which he lives in Mumbai with Bhakti and his daughter Diya.   Get in touch with the Pop duo on popsinapod@gmail.com Follow Pops In A Pod Instagram - https://www.instagram.com/popsinapod/    Facebook - https://www.facebook.com/popsinapod  Youtube - https://www.youtube.com/c/PopsinaPod Nadir is a media and advertising professional with 17 years of experience, out of this Nadir spent a decade in TV and digital video production – producing, directing, developing content, and writing.  www.linkedin.com/in/nadir-kanthawala-47249814/  Peter is a marketing guy. He has a decade of experience working with companies ranging from startups to public listed companies. https://www.linkedin.com/in/peterkotikalapudi/

Host Dr. John Sweetenham and guests Dr. Karen Reckamp and Dr. Harpreet Singh discuss the S2302 Pragmatica-Lung trial, a streamlined, real-world clinical trial that is poised to simplify and transform the entire clinical trials model as we know it. TRANSCRIPT Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, the associate director for cancer network clinical affairs at UT Southwestern's Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News Podcast.  Today, we are going to be discussing a streamlined, real-world clinical trial from the Southwest Oncology Group (SWOG), which is S2302, also known as the Pragmatica-Lung trial. This study is poised to simplify and transform the entire clinical trials model as we know it. Joining me for this discussion is the trial's lead investigator, Dr. Karen Reckamp. Dr. Reckamp is a clinical professor, director of the Division of Medical Oncology, and associate director for clinical research at Cedars-Sinai Samuel Oschin Cancer Center. I'm also delighted to welcome Dr. Harpreet Singh, the director of 1 of 3 divisions of oncology at the U.S. Food and Drug Administration. She will discuss the FDA's views on streamlining clinical trials to reach more representative groups of patients and will also more broadly address some of the key questions that regulators consider when deciding on whether real-world data can substitute for randomized controlled trials. Our full disclosures are available in the transcript of this episode, and disclosures relating to all episodes of the podcast are available on our transcripts at asco.org/DNpod. Dr. Reckamp and Dr. Singh, it's a great pleasure to have you on the podcast today. Dr. Karen Reckamp: Thank you for having us. Dr. John Sweetenham: Dr. Reckamp, I'm going to start with you if I may and ask if you could give us some background on S2302, the Pragmatica-Lung trial for non-small cell lung cancer. Dr. Karen Reckamp: Sure. The Pragmatica-Lung trial really started with the sub-study from Lung-MAP, which was called S1800A, and it was a randomized phase 2 trial that evaluated pembrolizumab and ramucirumab versus standard of care for patients who had previously received chemotherapy and immunotherapy with advanced non-small cell lung cancer and had had disease progression. And in this phase 2 trial, we found that there was an improvement in overall survival with a hazard ratio of 0.69% and survival of 14.5 months for pembrolizumab and ramucirumab, and 11.6 months for standard of care. And with that, we had again a randomized phase 2 trial, but the study was small. And so, trying to think about how to move this to the next level to get phase 3 data, we started thinking about how to do this in a way that would reduce the timelines and potentially move this treatment to patients more quickly than standard registrational, randomized phase 3 trials. And that's kind of where S2302 and Pragmatica-Lung started. Dr. John Sweetenham: So, can you tell us in a little more detail how the dramatically streamlined pragmatic design of this trial is going to hopefully simplify trial design and trial conduct in the future beyond non-small cell lung cancer?  Dr. Karen Reckamp: I think the important piece of this—and we have Dr. Singh here to speak to the FDA part—but this has been a partnership with the FDA and CTEP [NCI's Cancer Therapy Evaluation Program]. Really, our goal was to try and find a way to run trials in a more streamlined way. One of our colleagues at CTEP during this process said, “If this is not making you uncomfortable, then you're not doing it right.” So, the first thing we did was kind of lean into the discomfort because for those of us who have been writing trials and putting trials together for the last 20-plus years, this is dramatically different. And we're really looking at one question, and that is overall survival. We're trying to validate the overall survival we saw in S1800A. And with that, we stripped away all the unnecessary data collection that comes along with other types of registrational issues that come with randomized phase 3 trials. And then, we also looked at patient burden and really opened it up. So, again, pragmatically, making this practical, allowing investigators to be empowered to treat patients how they normally would in their own practice. And so, moving forward, again, for types of trials where we have drugs whose toxicity profiles are well known, they're used in practice but using novel combinations for a subset of patients who have limited treatment options available, this could really change the paradigm moving forward for these types of trials in multiple diseases. Dr. John Sweetenham: Yeah, thanks. And in addition to simplifying the trial design, obviously, one of the goals here is to have a study population which is more representative of the patients who are seen typically in community practice. Hopefully, we'll overcome some of the known disparities that we see in clinical trial accrual. Could you speak just a little bit to how the study design and the organization of the study helps to achieve that? Dr. Karen Reckamp: So, I think it's on several levels, but we are looking to allow this to be more generalizable and allow a more diverse population into this study. First, by again stripping down the eligibility criteria to only the absolute essential criteria for understanding our scientific question. And so, we don't require imaging studies to be uploaded or presented. If the patient has progression, it's based on the investigator's opinion. And so, we don't need to be searching for outside scans or things like that. We don't have tissue requirements, and we don't even actually have lab requirements. If this is a patient, you would treat your standard of care practice with the standard of care regimens; those are the labs that you do. So, it's all based on standard of care. So, by doing this based on standard of care, it really allows almost any patient to enroll. And then we have outreach. We have our DEI group and our community practices very well engaged to make sure that we have broad reach. Having this open through NCTN [NCI's National Clinical Trials Network] will make sure that we get this to multiple practices in far-reaching parts across the United States. Dr. John Sweetenham: Yeah, I think that's excellent. And you've already alluded to the fact that the data collection requirements for the study are going to be kind of pared down to the absolute minimum and that's going to include, I believe, toxicity reporting as well. So, can you comment a little bit on that and, specifically, what your plans are for reporting toxicity in this trial? Dr. Karen Reckamp: Yes, you're correct. This is significantly pared down from what we're used to doing. And so, most clinical trial offices are struggling with staffing and making sure that their patients have enough staff and that they have enough staff to get patients onto trials efficiently, and then getting the data in is always a challenge for sites. So, we have really, again, working with our partners, working with the FDA, and with CTEP, we have minimized what we are going to collect on patients. So, we're collecting survival and vital status on patients. We are collecting the background standard information that we collect on kind of prior therapies, and we are collecting only unexpected grade 3 and higher adverse events. And so, thinking about these drugs—ramucirumab and pembrolizumab—we know how these drugs work, we know the toxicity profile, we're using them in combinations and single agents in multiple tumor types. And so, thinking about most of the immune-related adverse events wouldn't even be reportable because they're expected. And so, a large number of data that is normally collected would not be collected here. And, as noted, we don't collect scans, we don't collect labs, we're not collecting con-meds, start and stop dates. A lot of that burden of data collection, but also data auditing and queries, goes away. It should be a significantly easier trial to perform by sites.  Dr. John Sweetenham: And can you just update us on the status of the trial right now? Dr. Karen Reckamp: We're in the process of pre-activation, and so, if you're an NCTN site, you can actually go in and do some pre-training and take a look at the draft protocol. And we are anticipating approval sometime in early March. Dr. John Sweetenham: Great. Congratulations on getting this trial launched and underway because I know that the word “groundbreaking” is used a lot, but I think that, obviously, if this trial proves to be the success that it looks like it will be, then it's going to have, I think, major implications for study design in the future. And that's going to lead me to ask a couple of questions to Dr. Singh. And the first one of those is the FDA's decision to consider data from a simplified pragmatic trial design like this, which uses more limited clinical information, is really kind of almost revolutionary. And could you comment a little on this from the FDA perspective and how you think it's going to influence the future of clinical trials and the future of cross-trials? Dr. Harpreet Singh: Well, thanks so much for the question, and thanks for having me. I want to push back on that just a little bit because I think, for what it's worth, the FDA has been advocating for trial efficiencies in oncology for many years. And, of course, as you know, our current commissioner, Dr. Robert Califf, is very vested in this concept. And certainly, the idea of pragmatic trial has been there in the field of cardiology for some time.  In terms of this trial, in particular, in coming to oncology, I do think actually putting pen to paper and drafting the protocol, which we did really in cohesion with SWOG and many calls with Karen and others who were a part of this, that collaborative piece, I think, is groundbreaking because what we saw here was a great deal of discomfort, actually around everything that we were stripping down. We sensed a lot of discomfort in terms of including various, like you mentioned, safety issues, safety reporting not being perhaps as rigorous as we're accustomed to seeing at the FDA. And certainly, investigators are accustomed to collecting other endpoints besides overall survival, like time to progression, but the real-world version of that, or time to next therapy. And so, one very difficult lesson that I've had to learn, and we've had to learn, is that you have to really learn to say no to some very interesting trial design elements that are not essential to the big question here, which is, does this combination regimen offer an improvement in survival over the control? So, while I do think the actual organizational and structural piece of this, now that it's actually stood up, is groundbreaking, I think that the idea of pragmatic trials and incorporating clinical care into the idea of answering a clinical question as opposed to the traditional randomized clinical trial is a concept that's been around. I'm just thrilled to see it actually occur in this very, I think, ideal setting for patients with lung cancer. Dr. John Sweetenham: Yeah, absolutely. I want to broaden the scope of what we're discussing here just a little bit, perhaps to talk a little more about the “real world” and “real-world data.” More real-world data is being considered in regulatory decision-making. And one of the questions I have, again, from an FDA perspective, is that everyone still, I think, regards randomized controlled trials as the gold standard for evaluating efficacy if not effectiveness, of various interventions. What are the key questions that you consider when deciding whether any kind of real-world data analysis is a good substitute for a randomized controlled trial?  Dr. Harpreet Singh: Well, thank you for the question about how FDA considers real-world data when we consider this to be appropriate. There are many nuances to this. So, first of all, what is real-world data? And there's actually a distinction between real-world data, which is just simply a source used in observational studies traditionally. But real-world data is not specifically a trial design; it's just data. Whereas real-world evidence, which is evaluating the benefits and risks which are derived from real-world data, may come from things like electronic health records. It's not either-or. So, for example, in a pragmatic trial, you could use a blended approach where you have some components of real-world data or real-world practice, which we may consider kind of part of real-world data, but while retaining some elements of randomized control trials. So, I think when FDA considers real-world evidence, so I'll say that instead of data, it usually would be a source like a very high-quality registry or data obtained through a very well-designed observational study. And this would be in settings of perhaps super rare diseases in which randomization is either not feasible or, in some cases, where you may have preliminary data which suggests that randomization is not ethical. But we agree with the general idea that the gold standard is randomization.  And that's what I love about this pragmatic trial, is that you are retaining the benefit of randomization while bringing pragmatic elements in, bringing the trial to patients and really incorporating clinical practice into the trial, as opposed to the reverse, where you're having patients enrolled on a traditional trial where the visits are outside of routine. Dr. John Sweetenham: Thanks for drawing that distinction between real-world evidence and real-world data because I think the two expressions are sometimes used a little carelessly, as maybe I just did. But certainly, one of the things that I've observed over the last several years since we started to incorporate real-world data or real-world evidence into our kind of oncology lexicon is that real-world data has been used in a fairly relaxed, let's say, way and certainly any relatively small series which has been registry based or retrospective, there's been a tendency to use this term called real-world data, which personally, I've certainly seen applied to patients who are undergoing very intensive therapies such as CAR T. And certainly, when I look at the patient characteristics in those elements of so-called real-world data, it's a long way from the real world that I'm familiar with in my own practice. And so, I do think that the term has been used very loosely. And your point about real-world evidence is an important one, I think. People are still questioning whether real-world evidence in oncology is truly valid. And I think to some extent, you've already answered that question.  Do you think that there are mistakes and pitfalls that investigators can avoid when they're looking at real-world evidence? Dr. Karen Reckamp: Sure. I mean, I think the first point of clarification is, are we looking at this evidence to support use of an oncology drug in clinical practice, or are you an investigator working to bring real-world evidence to the FDA for drug approval? But either way, no matter what scenario you're in, I think the first question you must ask yourself is, is this data fit for purpose? And what does that actually mean, ‘fit for purpose'? And I think it goes to things like, are the patients well-matched? So, there's this very complex process, but the concept is not complex of propensity score matching, which our statisticians do for us beautifully. But this idea of are the patients in this data set that you're looking at, this is just a collection of data, right? How relevant is it to the patient in front of you? Is there some sort of matching that's going on in terms of patient characteristic?  After that, you have to ask yourself about this kind of array of epidemiologic biases that are inherent in non-randomized comparisons. Like, is this contemporaneous data? So, if this data set came from a group of patients who started their therapy—this goes to the idea of the index date, okay, start of therapy—has the standard of care changed? Has supportive care become increasingly better? Obviously, the answer to that is yes. And so, if you have these contemporaneous mismatches, then can you actually really rely on this real-world data or evidence, either one, as you're applying it to your patient? So, I think if it's for regulatory purposes, certainly you could avoid many mistakes by coming to the FDA early and often, which we always recommend. And if it's you as a clinician, as a health care provider, looking at this collection of data, I think you do have to walk yourself through in a really basic kind of logical process of, “how well does this data apply to the scenario in which I want to use this therapy?” So, index date, selection, timing, patient characteristics, things like that. Dr. John Sweetenham: Yeah, great, thanks. And I'd like to maybe ask both of you for your comments on one final question, and this is circling back to the S2302 study. Intrinsic to the study design and the concept is that the population in this study will be truly representative of the “real world.” My two questions to both of you will be, first of all: What is the gold standard for representative? In other words, what does that really mean to have a representative population of patients with advanced non-small cell lung cancer? And secondly, do you have any safeguards in place in the course of the study designed to make sure that that study population doesn't get skewed in some way so that it becomes unrepresentative of the real world? So, Dr. Reckamp, maybe I can start with you and ask you for your comments about that. Dr. Karen Reckamp: Thank you. I think that's a very good question and something that we grappled with as we designed this study and really did keep coming back to that. So, I think when we talk about representation, most randomized trials don't have broad representation. They are very specific populations that we curate in order to take as much variability out of the trial as possible so that we can investigate just the experimental arm versus standard of care or whatever we're evaluating. And here, we've consciously made an effort to say we want to know how this works in a real practice and make this as generalizable as possible while still being safe. So, we have the premise of keeping patients safe as the number one goal of this trial. And then, we want to look at the survival data. So, we actually did lower the bar a bit and changed our hazard ratio. Our hazard ratio was 0.69% for the phase 2 trial. We loosened that a little bit for the phase 3 trial, knowing that the patients that are coming on to trial are not going to be perfect patients, and there may be a little more coming together of those curves. That being said, randomization is what is supposed to wash away all sins, which has been said many times as we put this trial together. And so, the randomization is really the goal, to utilize the randomization process in order to make sure that there is balance and that we are getting representation on both sides that will help us understand how the investigational arm is really doing in this population. It's not going to be perfect, and we are allowing for performance status 2 patients. But I think we all believe that this is really important because there's a large proportion of patients who have performance status 2 who never go on to trials, but in the real world, we treat them generally with the standard of care options that we use. So, I think this is really important for moving things forward, and will be groundbreaking in that way, too. Dr. John Sweetenham: Great, thank you. And Dr. Singh, just to add to that, will the FDA be looking at this from the perspective of making sure that the study population as a whole—accepting that randomization will hopefully cancel out some of the potential pitfalls there—but will the FDA be looking to make sure that the population as a whole is truly representative of what's out there in the real world?  Dr. Harpreet Singh: We always look at the population. We are always hopeful that, in general, the population is reflective of the disease for which—in this case, lung cancer. I think in this case, we were very hands-on with developing the protocol, and it is our hope and it's our expectation, and I think it very much will happen that you are going to see a very diverse and representative, more generalizable population here. I just want to add a piece to this because remember that traditional randomized clinical trials typically do have a more homogeneous patient population because a lot of this is designed around a de-risking strategy when you're bringing new drugs to market. One of the reasons we felt so comfortable stripping away, as Karen mentioned, no lab criteria. If the clinician says, “I think you're fit for this regimen, go ahead and enroll them.” We pushed for inclusion of PS 2 patients. We, the FDA, did. So, yes, we're going to be looking, but we do really hope that these really streamlined inclusion and exclusion criteria allow for that. And so there's other things too, like race, ethnicity, age. And so it starts with not excluding patients based on perhaps unfair or arbitrary cutoffs like labs. Not to say that performance status is arbitrary. But in this case, if the clinician deems you fit for this therapy, that is between the patient and the investigator and their judgment, which is really part of the element of real-world trials and this pragmatic element too.  I also wanted to add on this idea of diverse representation, we expect there to be a lot of extra, for lack of a better term, noise, in this trial, even though it's randomized. And so, part of the negotiation around designing this trial was the need for an increased sample size to try to account for some of what we expect to be perhaps unequal randomization, perhaps in terms of patient characteristics on either side, perhaps patients lost to follow-up, etc. And so, when we talk about pragmatic trials, one element is that you probably often may need an increased sample size to account for the increase in heterogeneity, not only in your patient population but perhaps in monitoring as well. Dr. John Sweetenham: Well, thank you both, Dr. Reckamp and Dr. Singh, for a great discussion today and for sharing your insights on these developing trends in clinical trial design. Dr. Reckamp and Dr. Singh, we'll be watching closely to see how the trial performs in the coming months and advances the concepts of pragmatic trial design that Dr. Singh mentioned earlier within the FDA. We obviously are very excited to see whether this change in trial conduct will enable you to meet new groups of patients and ultimately improve outcomes for them. So, thanks once again for being with us today. Dr. Harpreet Singh: Thanks so much. Dr. John Sweetenham: And thank you to our listeners for your time today. If you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. John Sweetenham  Dr. Karen Reckamp  @ReckampK  Dr. Harpreet Singh  @harpreet_md Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn  Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Karen Reckamp: Consulting/Advisory Role: Amgen, Takeda, AstraZeneca, Seattle Genetics, Genentech, Blueprint Medicines, Daiichi Sankyo/Lilly, EMD Serono, Janssen Oncology, Merck KGaA, GlaxoSmithKline, Mirati Therapeutics Research Funding (Institution): Genentech/Roche, Janssen Oncology, Calithera Biosciences, Elevation Oncology, Daiichi Sankyo/AstraZeneca, Blueprint Medicines Dr. Harpreet Singh: None Disclosed

The Many Colors of Harpreet Singh Written by Supriya Kelkar

Dr HPM discusses a lot of things and questions with Dr .Harpreet Singh Dr . Harpreet Singh, PhD Assistant Professor Computer Science & Engg Dept, Thapar Institute of Engg & Technology, Patiala, Punjab - 147004, India. . Both Dr Tapan and Dr Hara Prasad are good friends and colleagues. The Points that are disscussed in this podcast includes :- Dr Harpreet's educational training , his healthcare projects in collaboration with PGI Chandigarh. He explains how from a computer engineer he shifted to healthcare domain research due to his personal story inorder to make more impact in the lives of common man. He shares about some of his recent patents. Towards the end he also shares how his journey has been till now and how he looks forward going ahead in time as "entrepreneurship" is going to be next big thing. He has shared few tips and kep points for young Indian graduates. If any body is interested in connecting with Dr Harpreet Singh to know and explore more about life, mentorship ,public health research , entrepreneurship feel free to connect with him through his social media handle :- (1)Email :- akalharpreet@gmail.com

In today's episode of the Life Leadership Podcast, I am speaking to Harpreet Singh Harpreet is a Highly accomplished and multifaceted business management professional with 10+ years of success and history in driving rapid business growth and exceeding million-dollar business targets at companies such as Amazon, Nestle, Sony, Samsung, and Tech Startup. He has a strong background in leadership, stakeholder management and devising and implementing business growth strategies. Throughout his career, Harpreet has demonstrated the ability to take on bigger challenges. He strongly believes in working backwards from customer needs and building long-term mutually beneficial relationships with strategic partners. In today's episode Harpreet shares on – What it takes to transition from a Fortune 500 Company to working at a start-up, and the key differences in experience and exposure between the two With change being a constant, what we can do to effectively adapt What goes into a product launch & GTM strategy, leveraging his experience from one of the world's largest tech multinationals His international exposure and associated challenges The core skills he has honed to enable both business growth and his own career acceleration You can connect with Harpreet on LinkedIn at - https://www.linkedin.com/in/harsinghpreet/ The Life Leadership Podcast – with Leila Singh, is all things Coaching, Career & Personal Branding! This podcast is for ambitious career professionals, especially aspiring executives, working in the technology industry, wanting to uncover your real potential, create new possibilities and accelerate your career - to BE DO & HAVE more, whilst redefining your success, in work, relationships, health and much more. Life Leadership: Creating a life and career of choice, fulfilment and new possibilities! As well as discussing common coaching topics and challenges that my clients overcome, I will also explore aspects of career advancement and personal branding in the workplace.  And of course, continue to interview high-achieving leaders and execs in the tech space, who have carved out a successful career in their field, overcome challenges, and are openly willing to share their career journey, learnings and insights with you. Please SUBSCRIBE to this podcast, leave a REVIEW and SHARE with those that may benefit from this content. If you would like to learn more about working with me, Direct Message me on LinkedIn or email me at ⁠⁠hello@leilasingh.com⁠⁠ Connect directly with me here - ⁠⁠www.linkedin.com/in/leila-singh/⁠⁠ Register here to receive your copy of The mi-brand Personal Brand Playbook - ⁠⁠www.leilasingh.com/go/playbook⁠⁠ And check out - >>> This article by https://BestPodcasts.co.uk, who curated a list of the Best Career Podcasts of 2023, offering unique and actionable insights to help you achieve your career goals - ⁠⁠⁠⁠⁠https://www.bestpodcasts.co.uk/best-career-podcasts/⁠⁠ with our podcast ‘Life Leadership' featuring in the Top 5! >>> https://blog.Feedspot.com whose editorial team extensively researched and curated a list of the Top 15 Life Leadership Podcasts across all platforms, featuring 'Life Leadership' in the Top 3! With ranking based on factors including - Podcast content quality - Episode consistency - Age of podcast - Engagement & shares of the podcast across social platforms. ⁠⁠15 Best Life Leadership Podcasts You Must Follow in 2023 (feedspot.com)

At present, America has a sick care system where we wait until people are ill before we intervene.But what if wearable technology could serve as a kind of check engine light, letting us know when our health data is off?What if wearables could help us prevent disease and make better decisions for our health on a daily basis?Harpreet Singh Rai is the CEO of Oura, a health technology company on a mission to help people improve their sleep, understand their bodies and transform their health. Harpreet's team makes the Oura Ring, the most accurate sleep and activity tracker on the market. Harpreet spent 10 years in the finance space, serving as an Analyst with Morgan Stanley and Portfolio Manager at Eminence Capital before joining Oura in 2017.On this episode of HLTH Matters, Harpreet joins hosts Dr. Gautam Gulati, Dr. Jordan Shlain and Patricia Bradley to explain what differentiates the Oura Ring from other wearables and discuss its potential to become a clinically validated medical device. Harpreet shares his vision to expand the adoption of Oura through corporate partnerships, describing what his team does to keep user data private. Listen in for Harpreet's insight on how wearables predict illness (including COVID-19) and learn how the Oura Ring can help you make better daily decisions to improve your health.Topics CoveredWhat inspired Harpreet's passion for technology and health and how he got involved with the team at OuraWhat differentiates the Oura Ring from other wearablesThe potential for the Oura Ring to become a clinically validated medical deviceHow the Oura Ring predicts COVID-19 2 to 3 days before symptoms presentHarpreet's insight on increasing adoption of Oura through partnerships with corporate organizations and healthcare payers and providersWhat Oura does to ensure GDPR and HIPAA compliance and keep user data privateThe benefit of Oura's suggest-and-confirm methodology (and how Harpreet's team plans to expand the feature)Why Oura focuses on deviation vs. absolute numbers to inform behavior changeOura's long-term vision to support health as a daily practiceHow Oura helped the NBA maintain the ‘bubble' during the pandemic Connect with Harpreet Singh RaiOura Connect with Dr. Gautam Gulati, Dr. Jordan Shlain & Patricia BradleyHLTHDr. Gulati on TwitterDr. Gulati on LinkedInDr. Shlain on TwitterDr. Shlain on LinkedIn ResourcesOura's Research & Validation Blog'Feasible Assessment of Recovery and Cardiovascular Health: Accuracy of Nocturnal HR and HRV Assessed Via Ring PPG in Comparison to Medical-Grade ECG' in Physiological Measurement‘The Promise of Sleep: A Multi-Sensor Approach for Accurate Sleep Stage Detection Using the Oura Ring' in Sensors‘Feasibility of Continuous Fever Monitoring Using Wearable Devices' in Nature‘Feasibility of Continuous Distal Body Temperature for Passive, Early Pregnancy Detection' in medRxiv‘Nocturnal Finger Skin Temperature in Menstrual Cycle Tracking: Ambulatory Pilot Study Using a Wearable Oura Ring' in BMC Women's Health‘Ultradian Rhythms in Heartrate Variability and Distal Body Temperature Anticipate Onset of Luteinizing Hormone Surge' in Scientific Reports‘WVU Rockefeller Neuroscience Institute Announces Capability to Predict COVID-19 Related Symptoms Up to Three Days in Advance' in WVU Medicine News‘The US Military's Latest Wearables Can Detect Illness Two Days Before You Get Sick' in Defense OneFitbit Health SolutionsGDPR ComplianceHIPAA ComplianceHippocratic Oath 2.0‘The NBA Bubble Has Rolled Out Some Wild Technology to Help Keep Players, Coaches and Staff COVID-Free' in Business Insider Introductory Quote[34:12] “We call a lot of what we do in the app, we call it ‘look within.' People are pulled to it. What changed? Why did my data change? What did I do yesterday? You actually ask yourself, and that's where behavior change happens.”

Carl Safina is a world-renowned ecologist and Best Selling Author. In this episode, Harpreet discusses how humans and humans' behavior impact the lives of wildlife and their culture. Follow Carl Safina Here: Website: https://www.carlsafina.org/ Safina Centre: https://www.safinacenter.org/ Instagram: https://www.instagram.com/csafina/ Twitter: https://twitter.com/carlsafina Facebook: https://www.facebook.com/CarlSafinaAuthor/ Follow Harpreet Here: TikTok - https://www.tiktok.com/@theharpreetsingh? Instagram - https://www.instagram.com/theharpreetsingh.ca/

Julie Lythcott-Haims is a New York Times bestselling author of the anti-helicopter parenting manifesto 'How To Raise An Adult'. Her Latest book - Your Turn: How To Be An Adult has already been called a 'groundbreakingly frank' guide to adulthood. In this book, Harpreet and Julie discuss what it takes to be a good adult and a good parent. You Can Follow Julie Here: Website - https://www.julielythcotthaims.com/ Facebook - https://www.facebook.com/jlythcotthaims/ Twitter - https://twitter.com/jlythcotthaims Instagram - https://www.instagram.com/jlythcotthaims/ Learn more about Julie's Pod Here - https://jlythcotthaims.bulletin.com/ Follow Harpreet Here: TikTok - https://www.tiktok.com/@theharpreetsingh? Instagram - https://www.instagram.com/theharpreetsingh.ca/

“…People have started focussing on generation of money but are still ignoring part of managing money…”"... लोगों ने पैसा बनाने पर ध्यान देना शुरू कर दिया है लेकिन अभी भी पैसे के प्रबंधन के हिस्से की अनदेखी कर रहे हैं ..."Meet Harpreet, a wealth manager and financial literacy advocate currently based out of Chandigarh. Harpreet has worked in multiple functions in his decade long career. He most recently left Amazon India where he worked as a Product Manager. He completed his MBA from IIM Ahemdabad, prior to which he worked in an education startup. After completing his Computer Science Engineering from NIT Jalandhar and worked for Fiserv India. His passion for numbers, patterns and understanding the nature of money generation has now catapulted him into being a full time investor, primarily in the equity markets. He is passionate about increasing people's financial literacy and has been designing curricula around that. Harpreet is a close friend and the initial phases of our career journeys has been very similar. We have been working together since Aug 2021 towards financial literacy.This episode was recorded in April 2021.Know more about him - https://www.linkedin.com/in/harpreetsinghchawla/Subscribe and Follow SCM - https://linktr.ee/suchconversationsmatter#FinancialLiteracy #FinancialPlanning #Investment #MoneyManagement #Adulting #Savings #MutualFunds #Stocks #StockMarket  #EducationReform #SaurabhNanda  #SuchConversationsMatter #IndianPodcast #SpotifyPodcast #Podcast #GooglePodcast #ApplePodcast 

Harpreet Singh was travelling to India for a family emergency. Despite having what he thought was all the valid documents, he had to go through a lot of hassle to be able to board a Qantas flight at the Melbourne Airport.

Harpreet Singh, Business Head – Digital Lending & Cards, Intellect Design ArenaSecurity and scaleability are the watchwords but banks also need a fast, efficient credit decisioning process. Consumers are used to dealing with BigTech firms that respond in seconds. They are no longer prepared to wait days for decisions whether in their personal or business lives. Nor are they likely to be satisfied with traditional lending products in the coming era of hyperpersonalisation. Harpreet Singh, Business Head – Digital Lending & Cards at Intellect Design Arena, takes Robin Amlôt of IBS Intelligence through the key lending trends and technologies in play. 

Around the launch of the new Gen 3 Oura ring, Justine and Jenna got a chance to chat with Oura Ring CEO Harpreet Singh Rai! --- Support this podcast: https://anchor.fm/samebrain/support

Harpreet Singh is the founder and owner of Muscle Honey. He has planted hives over the east coast of Australia. When he's not a beekeeper, he's a full-time finance business partner. In this week's episode, we unpack bee facts, coping with grief, viral tiktoks, and how stress is vital to growth.Connect with HarpreetWebsite https://www.musclehoney.com.auInstagram https://www.instagram.com/muscle.honey/Tiktok https://www.tiktok.com/@musclehoney?00:00 Intro02:17  How muscle honey started05:07 Tiktok viral videos and ASMR08:05 Starting an organic farm10:15 Harpreet on resilience and grief13:56 Working solo on muscle honey16:15 Marketing from spoon to mouth17:36 The 2019 Australian bushfires's impact on the hives21:29 Stress is key to growth26:11 The queen and the collective colony31:46 Getting stung by bee and bee traits34:07 A bee's typical day36:47 Learning from bees38:08 Bee travel and orientation flights40:22 Myths about bees41:57 Brand integrity44:37 Outro

The American holiday season is in full swing — and it's time for deals galore. Gadgets, clothes, subscriptions, you name it. Gadgets 360 community manager and deals expert Harpreet Singh joins host Akhil Arora to talk about all things Black Friday 2021. We discuss how you can shop Black Friday deals while sitting in India, the things you should know about shipping and customs, and the best product categories that are worth exploring. Read: The best Black Friday 2021 deals We touch upon the early Black Friday deals we have seen at Amazon, Walmart, Best Buy, and Target — and the plethora of video gaming offers from Xbox, PlayStation, Steam, and Epic Games that are also available. Along the way, we look at why you shouldn't hang around too long on a good deal this year, and what you can expect from Black Friday's counterpart Cyber Monday. Follow Gadgets 360 on Facebook, Twitter, Instagram, and YouTube. Write to us at podcast@gadgets360.com Chapters Intro (00:00) What is Black Friday? (00:22) How can India shop? (02:14) The varied routes (03:58) Customs, customs (06:10) Ship with travellers (08:12) Deals, deals, deals (09:54) Best for India (13:12) Cyber Monday! (15:52) Tips and advice (17:29) Outro (20:19) Photo credit: Karolina Grabowska from Pexels

If you are looking for a perfect match for yourself or your child, then this is the way to go about it! Harpreet Singh takes forth the conversation with Anita Ram Sharma on what future marriages will look like.

A unique one stop destination for all things Interiors - AUX Home Auxilliaries or as we all know it - AUX Home, is a one of a kind luxury store for all your architectural spaces and needs. It a design hub, dealing in exclusive interior design, design products and lifestyle accessories that are presented under one roof at the Auxiliaries design showroom in New Delhi. The journey of Aux Home started in 2011 by its founders - Chitvi and Harpreet Singh. It has been a decade long passion project and a business which helps bring amazing international products to Indian homes. They believe in connecting Italy to India by sourcing products mainly from Italy as it has the finest brands and the finest designs and craftsmanship in the world. Aux Home believes in statement pieces which can accentuate any space. The internationally unique Auxiliaries concept offers the opportunity for customers to explore a broadly diverse range of premium brands like Molteni, Dada, Flos and Glas under one roof, accompanied and underpinned by outstanding service standards. Discussing all this and more on this episode of my podcast M-Power to get a glimpse of Chitvi and Harpreet's inspirational journey in bringing to life the one of a kind Aux home.

For this discussion, we turn to a great new article in the New England Journal of Medicine by Monica M. Bertagnolli and Harpreet Singh. This episode is also available as a multimedia blog post: https://survivingcancerembracinglife.com/2021/09/15/older-adults-underrepresented-in-cancer-research/

Know the first sign that your child is at risk of going in for gangs from Gira Bhatt, a Psychology Professor at KPU, in conversation with Harpreet Singh.

In light of the #OuraChallenge that went viral this week, we thought re-uploading this episode was super appropriate!! Harpreet Singh Rai is the CEO of Oura Health. Harpreet's view on sleep and its vital effect on every aspect of our lives are fascinating. Carving out a place in an already competitive field, especially for how small it is, Rai and Oura Health have solidified their position as an easy, convenient, and adaptive wearable. From getting coffee with the founder of a hemorrhaging company to becoming CEO only a year later Rai explains what he saw as important about this product he used before he ever had a stake in it, and the niche they found to grow and become one of the most successful wearables in the business. Where some may have faltered during the pandemic, Oura Health filled a unique necessity in their determination to do what they could as a company to help. Harpreet truly is inspiring and the technology they're working with could change more than just exercise, fitness, and baseline health. It could change monitoring fertility, illness, and even help prevent a pandemic on the level we've seen from ever happening again. Give it a listen.Youtube Link to This Episode Oura's InstagramOura's Instagram

Wearable fitness trackers. Everyone's got one these days…or maybe more than one. You can use them to keep tabs on everything from calories to steps to the amount of water you drink. But are you keeping track of your sleep? Not just how much, but how efficient your sleep is to help you recover and be ready for the challenges of the day ahead. That's the promise of the Oura Ring. It's been around for a while but the company behind it is really picking up steam and this week we talk with its CEO, Harpreet Singh Rai. He explains why the ring is a powerful device to help you reach your goals and keep you looking good while you do. In this episode you'll learn: What heart rate variability is and why it's an important health marker What sets the Oura Ring apart from other fitness trackers Tips to improve the quality of your sleep Simple changes to make your sleep more efficient How tracking your sleep may prevent the spread of illness Links Mentioned in the show: Oura Ring InsideTracker - CLICK for 25% OFF!

Bobby Umar is an inspirational speaker, coach, and best-selling author. Inc Magazine named him one of the Top 100 Leadership Speakers, alongside such noteworthy giants as Richard Branson, Brené Brown, and John Maxwell. Bobby is a 5x TEDx speaker, and also one of the top social media influencers in the world, with over half a million followers. He has been named the "2nd Best Business Coach to Follow" on Twitter and the "4th Best Leadership Influencer" according to Kred. In this episode, Bobby has shared golden tips on How to master the art of networking to become successful in your career. Show Notes: [01:18] | The Importance of Networking [04:38] | Plan Before Meeting Someone Special [08:20] | What is Authentic Networking [13:28] | Build Trust and Relationship with People [20:29] | Tactics in Networking with Important Person ]25:22] | Sharing Vulnerability Builds Strong Connection [31:25] | Caring and Communication Builds Connection [38:07] | Advice for Students in Canada [42:05] | Bobby Cares About This One Thing Today FOLLOW BOBBY UMAR: Website: https://www.raeallan.com/ Twitter: https://twitter.com/raehanbobby LinkedIn: https://www.linkedin.com/in/bobbyumar Instagram: https://www.instagram.com/raehanbobby Facebook: https://www.facebook.com/raehanbobby/ DYPB: https://www.dypb.ca/ FOLLOW HARPREET: TikTok - https://www.tiktok.com/@theharpreetsingh YouTube - https://www.youtube.com/c/HarpreetSinghLive Instagram - https://www.instagram.com/theharpreetsingh.ca/ __________ Intro Music: I Need You by LiQWYD https://soundcloud.com/liqwyd Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/3jOruYf Music promoted by Audio Library https://youtu.be/1EZZ3Z1oz4w

Airline CEO on Crafting Careers in Aviation | Harpreet A DeSingh | Airworthy Talks In this exclusive episode of Airworthy Talks, we connect you to India's first woman Airline CEO - Ms. Harpreet Singh. Tune in to hear her break several ceilings laid by the society with some truly airworthy ways to reach an airline's strategic management. Let's create an #AirworthyYou www.udaanaviationacademy.com

Your brain is the most essential organ in your body yet it is also the most ignored organ. The brain and spinal cord are intimately connected to every bodily system and organ, so when it is balanced everything in your body and mind will function more efficiently. It's vitally important to take proactive steps now, or you risk losing everything, including your ability to think clearly, be creative, remember details, solve problems and retain your memory. Dr. Kristen Willeumier is a neuroscientist with research expertise in neurobiology and neuroimaging. She is also an author of the book - Biohack Your Brain. In this episode, Dr. Kristen reveals how you can change your brain by making simple and easy modifications to your lifestyle. ___________ Show Notes: [03:18] Dr. Kristen shares the importance of brain health [04:50] Kristen reveals the best age to start working on your brain health [11:25] Dr. Willeumier talks on the significance of water and stay hydrated [23:14] What damages can be caused in the long run if not taking proper care of brain [34:21] Dr. Kristen shares her dad's story and how he inspired everyone around him [38:00] Kristen reveals the healthy foods to boost the brainpower [46:38] Dr. Kristen and Harpreet talks on sleep and the importance of enough rest for the brain [59:39] Harpreet asks Dr. Kristen - How International students can improve their brain health ___________ FOLLOW DR. KRISTEN: Website - https://www.drwilleumier.com/ Book - https://www.amazon.com/Biohack-Your-Brain-Cognitive-Performance-ebook/dp/B086JXQ5LC Instagram - https://www.instagram.com/kwilleumier FOLLOW HARPREET: TikTok - https://www.tiktok.com/@theharpreetsingh YouTube - https://www.youtube.com/c/HarpreetSinghLive Instagram - https://www.instagram.com/theharpreetsingh.ca/ ___________ Music (Intro): Live Together by Peyruis https://soundcloud.com/peyruis Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/3w5bq8F Music promoted by Audio Library https://youtu.be/nNsz8D7ylfM

Dr. Gillian Mandich is a Happiness Researcher with a Ph.D. from Western University in Health Science. She is also the founder of The International Happiness Institue of Health Science Research; Research Associate at The World Database of Happiness; co-lead investigator of The Canadian Happiness At Work-Study, and also a part of the Meant2Prevent research team at SickKids. She appears regularly in the media on shows such as The Social, Marilyn Denis, Breakfast Television, The Morning Show, and CBC; and is a top-rated keynote and TEDx speaker. ___________ Show Notes: Gillian describes why she is fascinated about researching Happiness... [02:36] Gillian talks more about Seeking Happiness is not the Final Goal... [07:20] Gillian discusses on 'Can we control our Happiness'... [12:27] Gillian describes indicators in How to be Happy... [16:25] Gillian shares daily practices to perform to surround yourself with Happiness... [29:44] Gillian talk about different steps to receiving Happines... [38:23] Gillian shares her visions and steps for her Legacy... [47:01] ___________ FOLLOW DR. GILLIAN MANDICH: Website: https://www.gillianmandich.com/ Media: https://www.gillianmandich.com/media FOLLOW HARPREET: TikTok - https://www.tiktok.com/@theharpreetsingh YouTube - https://www.youtube.com/c/HarpreetSinghLive Instagram - https://www.instagram.com/harpreet.singh.live ___________ Music: Hypnosis by Vendredi https://soundcloud.com/vendrediduo​ Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/3ejmYOC​ Music promoted by Audio Library https://youtu.be/CYX7qg1nmqU

In this episode, we meet Harpreet Singh Rai, CEO of ŌURA. ŌURA is the company behind the Oura Ring — a wearable health platform that delivers daily, personalized sleep, and overall health insights. With precise data and personalized guidance, ŌURA helps people better understand their health and live healthier, more fulfilled lives. To-date, ŌURA has sold 500,000 rings across 100+ countries. ŌURA has raised $148M in total funding to-date, recently closing a $100M Series C financing round led by The Chernin Group and Elysian Park; health investors Temasek, JAZZ Venture Partners, and Eisai Co., Ltd.; growth investors Bedford Ridge and One Capital from Japan. Existing investors who participated in the round include Forerunner Ventures, Square, MSD Capital, Marc Benioff, Lifeline Ventures, Metaplanet Holdings, and Next Ventures. In 2021, Fast Company listed ŌURA as the #5 (out of 10) Most Innovative Wellness Companies of 2021. Prior to joining ŌURA, Harpreet worked as a portfolio manager at Eminence Capital for 9 years and began his career in investment banking at Morgan Stanley. Harpreet majored in MEMS, Micro Electronic Mechanical Systems (sensor design) at the University of Michigan. In this episode, Harpreet and I chat about: How Harpeet's personal motivations and passion for technology and health led him to joining ŌURA and what it means to “own your health” Broader trends and landscape of the wearables industry — and how ŌURA's focus on clinical validation and accuracy is different from other wearable companies How ŌURA has partnered with numerous sports leagues, including the NBA, WNBA, UFC, and NASCAR to optimize performance and monitor a user's wellness What is required for wearables to reach their full potential: from consumer education to buy-in from healthcare stakeholders

Harpreet Singh Rai, the CEO of OURA Health Ltd, a Finish company which is making a huge splash in the wearable health and wellness space through its smart ring product.  He shares his stories how he became involved in the business and where he is planning to take it.  Great stories on how the product works and the benefits behind it, to the future growth and plans of the business.      Key Highlights Coming out college wanting to be an engineer, spending his first 10 years in the financial world on Wall Street, including Eminence Capital, multi billion dollar Fund, investing in tech  Combined his passion for health and wellness with his research in the tech space and getting into wearables as an early adopter/user Running into the co-founder at a grocery store – and hitting it off  Personally investing in the company in 2016 and joining the board.  Joining the company full time, in 2017 as President/CEO  Founders from Finland, country with great history in tech and health culture (Nokia, Polar, etc) OURA – focus on sleep tracking – massive benefits of the right amount and type of sleep (lack of sleep is detrimental to health) OURA ring – how it works, the data it measures, what it does and comparison to other wearables  “Sleep is the world's best (legal) performance enhancing drug” quote by Matthew Walker, Author of “Why we Sleep” What were the first users, beyond the early “bio hackers” adopters – awareness of Sleep becoming more main stream Sports connection, with NBA, UFC, NFL teams all inbound requests based on the product benefits  Covid influence on the business – very positive due to the ability to detect potential Covid infection before people show symptoms Shipped over 500k rings since inception, doubling every year – raised Series C, over US$ 100 mil  Great diverse group of investors globally, from Google to Temasek (Singapore Wealth Fund), Michael Dell and others. Strategic Investors supporting growth. Ouraring.com – only available online, shipping to 100 countries globally  - North America biggest markets, Europe and Asia growing  What's the future going forward.  Wearable market, 200 million units globally – smart phones over 1 billion.  Opportunities for more use cases to measure important health markers and build in preventive measures to detect heart attacks and others early signs of illnesses       Next steps after raising the money -  growth, SPACs, IPO and other options out there  Strong growth margins and profitable business  Challenges and how to overcome them – strong company values = solutions focused (find 3 solutions to every problem), Ubuntu (ancient African word -humanity to others)   About Harpreet Singh Rai Harpreet Singh Rai is the chief executive officer of Oura and a member of its board. His purpose is to be part of a team that is committed to improving the well-being of others. Under his leadership, Oura has grown to a team of nearly 100 employees and has launched its Generation 2 ring, shipping over 100,000 units to 90 different countries. He is responsible for Oura's vision and strategy and guides decisions that ensure the organization's financial health. Before Oura, Rai was a portfolio manager who led the technology, media and telecom portfolio at Eminence Capital for 9nine years. He began his career working in Morgan Stanley's merger and acquisitions group. Rai studied electrical engineering at the University of Michigan.   Follow us on our social sites for the latest updates Instagram: https://www.instagram.com/sportsentrepreneurs/ Facebook: https://www.facebook.com/marcusluerpodcast LinkedIn: https://www.linkedin.com/company/sports-entrepreneurs Website: https://marcusluer.com Podcast: https://marcusluer.com/podcast To get in touch, please email us at podcast@marcusluer.com   Feel Good by MusicbyAden https://soundcloud.com/musicbyaden Creative Commons — Attribution-ShareAlike 3.0 Unported — CC BY-SA 3.0 Free Download / Stream: https://bit.ly/_feel-good Music promoted by Audio Library https://youtu.be/bvgIqqRStcQ

Our guest today is Harpreet Singh Rai, the CEO of Oura. Oura is a smart ring that tracks your sleep and links how you sleep to your energy levels through the day. I have one, I love it. I have a bullet journal where I track all my habits and how I'm feeling throughout the day and what I learned is one of the biggest indicators to how I feel and how productive I am is directly tied to how I slept the night before. In this episode we discuss how underated sleep is, how Harpreet became the CEO of Oura and much much more.Sponsor: This episode is brought to you by Gorgias. Gorgias combines all your communication channels including email, SMS, social media, livechat, and phone, into one platform and gives you an organized view of all tickets. Sign up here and mention the Consumer VC podcast for two months free.Click Here to sign up.Some of the questions I ask Harpreet:You worked in banking for a long time. What compelled you to become an entrepreneur?Why did you decide to focus on sleep? What was the insight that led you to founding Oura?Why did you choose the ring as the type of wearable?When you were figuring out the data in the beginning, what was most surprising anWhat are the metrics/components to get a good night's sleep?What is Heart Rate Variance? How does that effect your sleep?Whilst sleep has been the positioning of Oura, how likely is it that we see fitness tracking being more of a focus?How do you calculate sleep score?How do you calculate readiness score?How does the form factor evolve from here?When do you think you found product-market fit?Why is it ring? - Accuracy and convenienceWhat was market validation to you?Rest modes - Matteo - to help save your lifeHow did you approach growth?When did you decide that you needed to fundraise?What was that process like? What was your strategy?What's the best piece of advice that you've received?

Amazon's annual shopping extravaganza and giant advertisement for its subscription service is back — for a two-day event on Monday, July 26 and Tuesday, July 27. Gadgets 360 community manager and deals expert Harpreet Singh joins host Akhil Arora to talk about all things Prime Day 2021. We discuss what you should expect (the best discounts are always on Amazon products) and how to prepare (set up wishlists and notifications). We also give you tips on deal hunting and tell you what to stay away from. Read: How to get the best Prime Day deals Lastly, we touch upon why you might want to wait for festive period sales (that are closer to Prime Day this time), and when you shouldn't. As always, we will highlight the best deals on Gadgets 360, so stick around. Follow Gadgets 360 on Facebook, Twitter, Instagram, and YouTube. Write to us at podcast@gadgets360.com Chapters Intro (00:00) What is Prime Day? (00:19) What to expect (03:13) Amazon is always on sale (05:02) How to prepare (06:37) What to do on sale day (09:44) The kinds of deals (12:25) Hey, impulse buyers (14:39) What to avoid (16:50) Prime Day vs festive sales (18:58) Outro (21:50)

In his childhood, Andrew had cancer twice and each time was given a 35% chance to pull through. Even after losing a part of his right leg and a small portion of his left lung, he continued working hard, never gave up, and eventually reached a level where he set multiple swimming world records. Andrew Haley is a three-time World and Paralympic Champion and multiple World Record Holder. He is also a Hall of Fame Swimmer and his story motivated and inspired thousands to 'Never Give Up'. ___________ Show Notes: Andrew shares his journey on when he represented Canada at International Games... [02:21] Andrew talks about CANCER and How he won that particular battle... [03:44] Andrew on achieving Success and become Resilient... [08:13] Andrew talks about How to stop doubting Yourself... [17:32] Andrew provides details on 'Sacrifices' needed to be best of the best... [24:12] Andrew Haley on changes he brought in his life after retirement from competitive swimming in 2008... [37:50] Andrew shares the 'One Lesson' everyone needed to hear... [48:46] ___________ Follow Andrew: Website: http://www.andrewhaley.ca/ LinkedIn: https://www.linkedin.com/in/ahaley1 Twitter: https://twitter.com/ahaleyca FOLLOW HARPREET: TikTok - https://www.tiktok.com/@theharpreetsingh YouTube - https://www.youtube.com/c/HarpreetSinghLive Instagram - https://www.instagram.com/harpreet.singh.live ___________ Music: Hypnosis by Vendredi https://soundcloud.com/vendrediduo​ Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/3ejmYOC​ Music promoted by Audio Library https://youtu.be/CYX7qg1nmqU

Harpreet Singh Rai is the CEO of Oura Health. Harpreet's view on sleep and its vital effect on every aspect of our lives is fascinating. Carving out a place in an already competitive field, especially for how small it is, Rai and Oura Health have solidified their position as an easy, convenient, and adaptive wearable. From getting coffee with the founder of a hemorrhaging company to becoming CEO only a year later Rai explains what he saw as important about this product he used before he ever had a stake in it, and the niche they found to grow and become one of the most successful wearables in the business. Where some may have faltered during the pandemic, Oura Health filled a unique necessity in their determination to do what they could as a company to help. Harpreet truly is inspiring and the technology they're working with could change more than just exercise, fitness, and baseline health. It could change monitoring fertility, illness, and even help prevent a pandemic on the level we've seen from ever happening again. Give it a listen.Youtube Link to This Episode Oura's InstagramOura's Instagram

In this episode of Lung Cancer Considered, Dr. Stephen Liu sits down with guest Dr. Harpreet Singh from the FDA to discuss the agency's oncology drug approval process. The interview also covers how new drug approvals are handled in other countries

Harpreet Singh Grover founded CoCubes.com, an online platform for assessments and hiring along with his batchmate Vibhore Goyal in 2007 after completing his graduation at IIT, Delhi.  CoCubes was acquired by Aon Hewitt in an all-cash deal in 2016. Harpreet has also authored a book titled Let's Build a Company along with Vibhore Goyal. This book is a tale of persistence & grit and about a company built in India by two Indian founders. It is written in the hope that entrepreneurs can avoid the mistakes Harpreet and Vibhore made and learn from what they did right.Harpreet is also an active angel investor, with his deals including Chaayos, ShopKirana, and Avail Finance. When it comes to entrepreneurship most people only talk about immersing themselves in the company they've been building while ignoring everything else. To contrast with this, during the podcast, Harpreet shares the emotional and personal aspects while making the tough decisions and the importance of spending time with family in an entrepreneur's life.Join this heart to heart conversation with Harpreet to know how entrepreneurs, while building their dream startup, compromise on their emotional and personal aspects, and how Harpreet's journey can add value to anyone who is doing a startup and experiencing the ups and downs while building a company in IndiaNotes - 02:47 - Harpreet's journey: Lowest point as an entrepreneur08:42 - “My best investments were done when I had less money.”15:12 - “At any point in your journey, if you've been in a tough spot, talk to someone who has been in that tough spot.”21:30 - “Companies are not sold, they are bought.”22:16 - Life after the acquisition 29:12 - Importance of having family time in an entrepreneur's life35:19 - What choices he would have changed in life, 10-12 years back?39:42 - Being an Entrepreneur: Solving for simple problems

I am in a conversation with Harpreet Singh Grover, the Co-Founder, and Ex-CEO of CoCubes, an online assessment platform. He is the co-author of the book: Let's build a company (https://letsbuildacompany.com/). He is also an entrepreneur and an angel investor. Apart from work, he is a mountaineer and ultrarunner. He is passionate about careers and parenting! Topics: Overview of CoCubes. Common areas of improvement observed as part of the online assessments. Average mindset. Gaps in the education system. The role of parents and teachers. Definition of 'Job Ready'. Advice to the youth. Insights from one of the chapters from his book - 'We do many things in life just because we can.' Connect with Harpreet: LinkedIn: https://www.linkedin.com/in/hsgrover/ Twitter: https://twitter.com/hsgrover Connect with me: LinkedIn: https://www.linkedin.com/in/gautamsrikrishna Twitter: https://twitter.com/gautamhs Facebook: https://www.facebook.com/gautam.srikrishna Music: https://www.purple-planet.com --- Send in a voice message: https://podcasters.spotify.com/pod/show/gautam-srikrishna/message

In this episode of the Net Nihung's Arena, Mandheer Singh speaks with Harpreet Singh Veerji about Montessori School and Gurmat principles. Bhai Harpreet Singh ji talks about how creating an environment of unrestricted learning is completely in line with Gurmat and the true nature of a Sikh. Our mission here at the Net Nihung's Arena is to highlight Sikhs from around the world by showcasing their professions, passions and perspectives through sharing ideas and entertaining discussions for the benefit of the Sikh Panth. Guest Info:website  https://www.kmschool.org/Here are the ways to work with us here at the Net Nihung's Arena: ⚡️BE A GUEST: Sign-up to be a guest on the podcast.  ⚡️SHARE: Share the podcast with friends and family. Connect with Mandheer Singh on Social Media:http://www.netnihung.com/https://twitter.com/netnihunghttps://www.facebook.com/netnihungsarenaQUESTION — Have a suggestion for a guest in the Net Nihung's Arena? Post in the comments section of this video!Subscribe to the Net Nihung's Arena: https://www.youtube.com/channel/UCsSLRIH08v1aTAHU1InVzlg?sub_confirmation=1--------- Gear Used To Create This Podcast -------Panasonic Lumix G7Shure SM7bCloudLifterMotu M4 Sound InterfaceElgato HD60 S Capture Interface

The buzz: “Data in the 21st century is like oil in the 18th century: an immensely, untapped valuable asset. Like oil, for those who see data's fundamental value and learn to extract and use it there will be huge rewards” [www.wired.com]. The digital world around us is supported by the evolving ecosystem of applications and services. Data flowing into this ecosystem is consumed in use case scenarios that help businesses drive better insights. The process of turning ‘crude' data into meaningful Information makes it analogous to the oil running our machines. Now organizations are striving to reduce technology debt by utilizing machine learning algorithms and statistical models to derive business decisions. How can organizations evolve to meet these challenges? We'll ask Amy Withrow at KraftHeinz and Harpreet Singh at Deloitte for their insights on The Kinetic Enterprise: Data Is The New Oil.

The buzz: “Data in the 21st century is like oil in the 18th century: an immensely, untapped valuable asset. Like oil, for those who see data's fundamental value and learn to extract and use it there will be huge rewards” [www.wired.com]. The digital world around us is supported by the evolving ecosystem of applications and services. Data flowing into this ecosystem is consumed in use case scenarios that help businesses drive better insights. The process of turning ‘crude' data into meaningful Information makes it analogous to the oil running our machines. Now organizations are striving to reduce technology debt by utilizing machine learning algorithms and statistical models to derive business decisions. How can organizations evolve to meet these challenges? We'll ask Amy Withrow at KraftHeinz and Harpreet Singh at Deloitte for their insights on The Kinetic Enterprise: Data Is The New Oil.

The buzz: “I am interested in the future because I expect to spend the rest of my life in the future” (C.F. Kettering). If your #1 business wish this holiday is knowing what 2019 holds for your company, your industry and the world, we've got the next best thing. We're bringing you six weeks of predictions from a total of 80 thought leaders about the technologies, strategies, and trends that can help you grow and compete in 2019 and beyond. Pour a cup of Joe, Earl, or Dom, and join us for SAP Game-Changers Radio 2019 Predictions – Part 3 live. You'll hear from Tom Raftery, SAP; Alistair Wheate, Onalytica; David Graham, City of Carlsbad, Ca; Kay Sargent, HOK; Devraj Bardhan, IBM; Frederick Ronse, Ovinto; Meg Divitto, Divitto Design Group; Harpreet Singh, Deloitte; Alexandra Witte, SAP; Kyle Tate , Eventful Conferences; Birgit Starmanns, SAP; Joe Renz, New Mobility Lab; Mike Lackey, SAP; William Newman, SAP; and Hudson Harris, HarrisLogic. Happy holidays from SAP Game-Changers Radio!

The buzz: “I am interested in the future because I expect to spend the rest of my life in the future” (C.F. Kettering). If your #1 business wish this holiday is knowing what 2019 holds for your company, your industry and the world, we've got the next best thing. We're bringing you six weeks of predictions from a total of 80 thought leaders about the technologies, strategies, and trends that can help you grow and compete in 2019 and beyond. Pour a cup of Joe, Earl, or Dom, and join us for SAP Game-Changers Radio 2019 Predictions – Part 3 live. You'll hear from Tom Raftery, SAP; Alistair Wheate, Onalytica; David Graham, City of Carlsbad, Ca; Kay Sargent, HOK; Devraj Bardhan, IBM; Frederick Ronse, Ovinto; Meg Divitto, Divitto Design Group; Harpreet Singh, Deloitte; Alexandra Witte, SAP; Kyle Tate , Eventful Conferences; Birgit Starmanns, SAP; Joe Renz, New Mobility Lab; Mike Lackey, SAP; William Newman, SAP; and Hudson Harris, HarrisLogic. Happy holidays from SAP Game-Changers Radio!

Harpreet Singh is Co-founder and Co-CEO of ExpertFi, as well as a Fellow at Harvard Innovation Lab. He is responsible for Experfy's strategy and operations. He is an entrepreneur with experience leading cross-functional teams in global execution of product development, business strategy, operations, and technology functions. With exceptional emphasis on structured governance, he managed the program management initiatives for sixty technology startups from Citigroup's e-Citi Venture Portfolio Office. In a later role as Director of Technology, also at Citigroup, he architected the infrastructure of global multi-tiered, web-based electronic exchanges. Harpreet subsequently established the Project Management Office (PMO) for FX Alliance, a global foreign exchange platform, where he was responsible for enabling project and risk management functions for New York, London and Tokyo locations. Harpreet earned Master's and PhD degrees from Harvard University, where he currently serves as a faculty member. In 2001, Harpreet co-founded the Sikh Coalition—a civil rights group—in the wake of hate crimes against Sikh-Americans after the September 11 attacks. In 2003, along with Desmond Tutu, Harpreet was honored with the James Parks Morton Interfaith Tribute by the Interfaith Center of New York for his work to help heal local communities on the grassroots level. Key Takeaways: [1:26] Dr. Singh breaks down the 3 characteristics of big data: volume, variety and velocity [4:11] How big data is being used in a way that small businesses can actually use [7:15] How big data has been used in conferences to aid in seating people, at a price that businesses can actually afford [9:21] How Experfy has been able to recruit and retain some of the big names in the data scientist world [10:15] Using big data can help your company automate things previously done manually, drive down your prices and help you expand [14:34] The future of big data and analytics [16:00] Describing the Harvard Innovation Lab